Comparison of scales for evaluating premenstrual symptoms in women using oral contraceptives
- PMID: 18447656
- DOI: 10.1592/phco.28.5.576
Comparison of scales for evaluating premenstrual symptoms in women using oral contraceptives
Abstract
Study objective: To compare two scales used in research to evaluate daily premenstrual mood symptoms during use of a monophasic oral contraceptive.
Design: Subanalysis of data from a prospective study.
Setting: University-affiliated medical center. SUBJECTS; One hundred two reproductive-aged (18-48 yrs) women taking a monophasic oral contraceptive containing ethinyl estradiol and drospirenone in the standard 21-7 fashion (21 days of hormones followed by 7 days of placebo), and who had self-identified premenstrual symptoms of headache, mood changes, or pelvic pain.
Intervention: Subjects completed a single-item questionnaire, the Scott & White Daily Diary of Symptoms, and a multiple-item questionnaire, the Penn State Daily Symptom Report (DSR), to assess their premenstrual symptoms. The Scott & White diary used a visual analog scale of 0-10 to assess pelvic pain, headache, and mood (a composite of anxiety, depression, and irritability). The Penn State DSR contained 17 items: 10 behavioral and seven physical components, each rated on a scale of 0-4, with one item that specifically rated mood swings.
Measurements and main results: Scores from the two scales were compared by using Spearman correlation coefficients, the Kendall W for concordance, and linear regression of ranked sums for study cycles. The Scott & White mood score significantly correlated with the total of the 17 items on the Penn State DSR, as well as the 10 behavioral items, the seven physical items, and the single mood-swing item (p<0.0001); specific coefficients of concordance were 0.44, 0.23, 0.10, and 0.28, respectively, and R2 values were 0.39, 0.39, 0.30, and 0.34, respectively. The daily Scott & White mood score was positively correlated with all 17 elements of the Penn State DSR (0.25-0.57). The greatest correlation was seen with the mood-swing element. Both instruments demonstrated the same patterns during the 21-7 oral contraceptive cycle, with symptoms increasing immediately before and peaking during the 7-day hormone-free interval.
Conclusion: A single-item daily mood score using a rating scale of 0-10 was concordant with a relatively complex 17-element symptom index and demonstrated the same pattern of change during cycles of oral contraception. The simple scoring system offers an advantage, especially in clinical studies of long duration.
Similar articles
-
Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen.Am J Obstet Gynecol. 2006 Nov;195(5):1311-9. doi: 10.1016/j.ajog.2006.05.012. Epub 2006 Jun 21. Am J Obstet Gynecol. 2006. PMID: 16796986 Clinical Trial.
-
A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms.J Reprod Med. 2002 Jan;47(1):14-22. J Reprod Med. 2002. PMID: 11838304 Clinical Trial.
-
Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval.Headache. 2007 Jan;47(1):27-37. doi: 10.1111/j.1526-4610.2007.00650.x. Headache. 2007. PMID: 17355491 Clinical Trial.
-
[Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].Minerva Ginecol. 2007 Aug;59(4):415-25. Minerva Ginecol. 2007. PMID: 17923832 Review. Italian.
-
Added benefits of drospirenone for compliance.Climacteric. 2005 Oct;8 Suppl 3:28-34. doi: 10.1080/13697130500330309. Climacteric. 2005. PMID: 16203653 Review.
Cited by
-
Migraine start, course and features over the cycle of combined hormonal contraceptive users with menstrual migraine - temporal relation to bleeding and hormone withdrawal: a prospective diary-based study.J Headache Pain. 2020 Jun 24;21(1):81. doi: 10.1186/s10194-020-01150-1. J Headache Pain. 2020. PMID: 32580694 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical